Acadia Pharmaceuticals financials
$20.22−1.51%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.07B | $957.8M | $726.4M | $517.2M | $484.1M | $441.8M | $339.1M | $223.8M | $124.9M | $17.3M |
| Gross profit | $982.5M | $876.0M | $684.8M | $507.1M | $465.0M | $431.5M | $327.7M | $211.4M | $115.8M | $14.3M |
| Gross margin | 91.7% | 91.5% | 94.3% | 98.0% | 96.0% | 97.7% | 96.7% | 94.5% | 92.7% | 82.3% |
| Operating income | $104.8M | $84.3M | -$73.4M | -$223.6M | -$170.4M | -$286.6M | -$246.5M | -$247.4M | -$292.4M | -$272.8M |
| Net income | $391.0M | $226.5M | -$61.3M | -$216.0M | -$167.9M | -$281.6M | -$235.3M | -$245.2M | -$289.4M | -$271.4M |
| Net margin | 36.5% | 23.6% | −8.4% | −41.8% | −34.7% | −63.7% | −69.4% | −109.6% | −231.7% | −1565.9% |
| Diluted EPS | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | $-1.60 | $-1.94 | $-2.36 | $-2.34 |
| EBITDA | $116.6M | $100.2M | -$67.8M | -$221.6M | -$167.1M | -$283.7M | -$243.8M | -$244.4M | -$289.7M | -$271.0M |
| Operating cash flow | $109.8M | $157.7M | $16.7M | -$114.0M | -$125.7M | -$136.2M | -$151.1M | -$167.5M | -$217.8M | -$208.4M |
| Free cash flow | $105.1M | $157.2M | $16.7M | -$114.0M | -$126.8M | -$143.8M | -$152.3M | -$169.6M | -$218.6M | -$209.9M |
| Diluted shares | 169.9M | 166.4M | 163.8M | 161.7M | 160.5M | 157.3M | 147.2M | 126.6M | 122.6M | 115.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $177.7M | $319.6M | $188.7M | $114.8M | $147.4M | $326.0M |
| Short-term investments | $642.0M | $436.4M | $250.2M | $302.0M | $373.3M | $305.9M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.56B | $1.19B | $749.0M | $587.8M | $700.1M | $782.6M |
| Total liabilities | $336.8M | $455.0M | $317.2M | $187.4M | $159.2M | $155.6M |
| Shareholders' equity | $1.23B | $732.8M | $431.8M | $400.4M | $540.9M | $627.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology